-
Mylan seeks approval for generic diabetes drug
PITTSBURGH — Generic drug maker Mylan is challenging the patent on a drug used to treat diabetes, the company said Monday.
Mylan said that it was sued by Takeda Pharmaceutical, Watson Pharmaceuticals and Andrx Labs in the U.S. District Court for the Southern District of New York in response to Mylan's filing a regulatory approval application with the Food and Drug Administration for a generic version of Actoplus Met XR (pioglitazone hydrochloride and metformin hydrochloride) extended-release tablets in the 15-mg/1,000-mg and 30-mg/1,000-mg strengths.
-
CVS Caremark study: Pharmacy Advisor improved diabetes Rx initiation, adherence rates
WOONSOCKET, R.I. — A CVS Caremark study found that the company's integrated pharmacy-based program — Pharmacy Advisor — increased medication adherence rates and physician initiation of prescriptions for concomitant medications, improving care for diabetes patients and resulting in savings for health plans, the company announced on Monday.